# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
After the market close on Monday, Hims & Hers Health reported strong first-quarter results that included revenue of $278.2 ...
Hims & Hers Health reported total revenue of $278.2 million, a 46% year-on-year growth and higher than Street expectations ...
Deutsche Bank analyst George Hill maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from ...
CMND: 60% | Clearmind Medicine shares are trading higher after the company signed an exclusive patent licensing agreement with ...
Piper Sandler analyst Korinne Wolfmeyer maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and raises the price tar...
On Monday, major U.S. stock indexes experienced gains, with the S&P500 closing nearly 1% higher at 5,180.74